Search

Displaying results 6871 - 6880 of 10000 in total
  1. Drug

    Tilia cordata pollen

    go.drugbank.com/drugs/DB10954
    Approved

    Tilia cordata pollen is mainly used in allergenic testing.

  2. Drug

    Hordeum vulgare pollen

    go.drugbank.com/drugs/DB10961
    Approved

    Hordeum vulgare pollen is mainly used in allergenic testing.

  3. Drug

    Pseudotsuga menziesii pollen

    go.drugbank.com/drugs/DB10986
    Approved

    Pseudotsuga menziesii pollen is mainly used in allergenic testing.

  4. Drug

    Maclura pomifera pollen

    go.drugbank.com/drugs/DB10988
    Approved

    Maclura pomifera pollen is mainly used in allergenic testing.

  5. Drug

    Mizagliflozin

    go.drugbank.com/drugs/DB19036
    Investigational

    Mizagliflozin is under investigation in clinical trial NCT05721729 (Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions).

  6. Drug

    Dimetotiazine

    go.drugbank.com/drugs/DB08967
    Approved

    Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.

  7. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  8. Drug

    Davalintide

    go.drugbank.com/drugs/DB14956
    Investigational

    Davalintide is under investigation in clinical trial NCT00785408 (Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects).

  9. Drug

    MK-8189

    go.drugbank.com/drugs/DB19153
    Investigational

    MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

    Synonyms: 4-PYRIMIDINAMINE, 2-METHYL-6-(((1S,2S)-2-(5-METHYL-2-PYRIDINYL)CYCLOPROPYL)METHOXY)-N-((5-METHYL-1,3,4-THIADIAZOL-2-YL)METHYL)-
  10. Drug

    Dubermatinib

    go.drugbank.com/drugs/DB15187
    Investigational

    Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).